Reversal agent for FXa inhibitors is effective and safe in interim analysis of ANNEXA-4 trial
ACC 2018 Prof. Connolly summarizes the results of the interim analysis of the ANNEXA-4 trial: andexanet was effective in the reversal of the effect of FXa inhibitors and reversed FXa-associated bleedings in patients with acute major bleedings.
This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.
Dr. Stuart Connolly is a professor of Medicine at McMaster University and a cardiac electrophysiologist at Hamilton Health Sciences.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.